Protara Therapeutics, Inc.
TARAAnalyst Consensus
Price Target Trend
Rating Trend
Recent Price Targets
| Date | Firm | Analyst | Target | Price Then | Source |
|---|---|---|---|---|---|
| Apr 16, 2025 | Scotiabank | George Farmer | $12.00(+200%) | $4.00 | TheFly |
Recent Rating Actions
| Firm | Action | Rating | Date |
|---|---|---|---|
| Oppenheimer | maintain | Outperform | May 20, 2026 |
| JP Morgan | maintain | Overweight | May 14, 2026 |
| HC Wainwright & Co. | maintain | Buy | Apr 29, 2026 |
| HC Wainwright & Co. | maintain | Buy | Feb 10, 2026 |
| HC Wainwright & Co. | maintain | Buy | Dec 3, 2025 |
| HC Wainwright & Co. | maintain | Buy | Nov 19, 2025 |
| HC Wainwright & Co. | maintain | Buy | Apr 28, 2025 |
| HC Wainwright & Co. | maintain | Buy | Mar 6, 2025 |
| Guggenheim | maintain | Buy | Dec 6, 2024 |
| HC Wainwright & Co. | maintain | Buy | Dec 6, 2024 |
| HC Wainwright & Co. | maintain | Buy | Nov 14, 2024 |
| Oppenheimer | maintain | Outperform | Aug 12, 2024 |
| HC Wainwright & Co. | maintain | Buy | Aug 8, 2024 |
| HC Wainwright & Co. | maintain | Buy | May 6, 2024 |
| Oppenheimer | maintain | Outperform | Apr 22, 2024 |
| HC Wainwright & Co. | maintain | Buy | Apr 8, 2024 |
| HC Wainwright & Co. | maintain | Buy | Mar 14, 2024 |
| HC Wainwright & Co. | maintain | Buy | Aug 4, 2023 |
| HC Wainwright & Co. | maintain | Buy | May 8, 2023 |
| HC Wainwright & Co. | maintain | Buy | May 1, 2023 |
| HC Wainwright & Co. | maintain | Buy | Mar 9, 2023 |
| HC Wainwright & Co. | maintain | Buy | Aug 10, 2022 |
| HC Wainwright & Co. | maintain | Buy | May 9, 2022 |
| Oppenheimer | maintain | Outperform | Nov 8, 2021 |
| HC Wainwright & Co. | maintain | Buy | Jun 4, 2021 |
Earnings History
Next report: Mar 9, 2027 · EPS est. $-0.38| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Nov 6, 2026 | $-0.35 | $-0.37 | — | — |
| Aug 11, 2026 | $-0.36 | $-0.33 | — | — |
| May 13, 2026 | $-0.31 | $-0.36 | — | — |
| Mar 10, 2026 | $-0.37 | $-0.32 | — | — |
| Nov 10, 2025 | $-0.31 | $-0.39 | — | — |
| Aug 11, 2025 | $-0.35 | $-0.43 | — | — |
| May 8, 2025 | $-0.29 | $-0.47 | — | — |
| Mar 5, 2025 | $-0.48 | $-0.57 | — | — |
News
Expect to complete enrollment of the BCG-Unresponsive registrational cohort of the ADVANCED-2 trial of TARA-002 in NMIBC by year-end 2026
Company remains on track to report interim results from Phase 2b cohort in 4Q 2026 NEW YORK, Oct. 15, 2026 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage biotechnology company developing transformative therapies for the treatment of cancer and rare diseases, today announced that it has completed enrollment of the Phase 2b, open-label dose confirmation phase of the THRIVE-3 clinical trial evaluating IV Choline Chloride in patients with intestinal failure who are d…
NEW YORK, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that management will present at the H.C. Wainwright 28th Annual Global Investment Conference on Tuesday, September 15, 2026, at 2:00 pm ET.
Bank of America Corp DE grew its stake in shares of Protara Therapeutics, Inc. (NASDAQ: TARA) by 86.7% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 925,918 shares of the company's stock after buying an additional 430,014 shares during
Protara Therapeutics is rated Buy, with a risk-adjusted fair value of $9.96 per share versus the current ~$4 price. TARA-002 targets NMIBC and Lymphatic Malformations; orphan drug indications offer significant upside, despite NMIBC's competitive landscape and lower CR rates. IV Choline Chloride, targeting severe choline deficiency in parenteral nutrition patients, could generate substantial revenue if approved, with pivotal data expected in 2026.